Completed OBSERVATIONAL NCT01741844

A Post Marketing Survey Study to Evaluate the Safety and Effectiveness of Intelence

Regulatory Post Marketing Surveillance of Intelence Tablet

Sponsor: Janssen Korea, Ltd., Korea

Conditions Acquired Immune Deficiency Syndrome

Updated 8 times since 2017 Last updated: Mar 31, 2016 Started: Sep 30, 2012 Primary completion: Jul 31, 2014 Completion: Jul 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01741844, this observational or N/A phase trial focuses on Acquired Immune Deficiency Syndrome and remains completed. Sponsored by Janssen Korea, Ltd., Korea, it has been updated 8 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed
Sep 2024 — Sep 2025 [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed

▶ Show 3 earlier versions

Apr 2018 — Jun 2018 [monthly]

Completed

Phase: PHASE4 → None
Feb 2017 — Apr 2018 [monthly]

Completed PHASE4
Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Sep 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Janssen Korea, Ltd., Korea

Data source: Janssen Korea, Ltd., Korea

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Daegu, South Korea